GT Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-19	-28.35	-13.16	-7.6	-20.88	-58.01
Stock-Based Compensation	0.47	0.43	0.23	2.2	7.65	33.93
Other Adjustments	13.67	15.93	-0.75	-5.28	0.01	0.54
Changes in Accounts Payable	0.1	-1.3	0.94	1.96	-2.03	7.08
Changes in Other Operating Activities	0.61	0.38	-0.16	-0.14	0.04	0.86
Operating Cash Flow	-13.18	-12.91	-12.9	-8.85	-15.22	-15.61
Proceeds from Sale of Investments	-	-	12.89	-2.01	12.15	-23.04
Investing Cash Flow	-	-	12.89	-2.01	12.15	-23.04
Long-Term Debt Issued	-	-	-	-	-	1.21
Net Long-Term Debt Issued (Repaid)	-	-	-	-	-	1.21
Issuance of Common Stock	5.55	5.5	2.98	6.27	-	41.11
Repurchase of Common Stock	-	-	-	-	-0.22	-
Net Common Stock Issued (Repurchased)	5.55	5.5	2.98	6.27	-0.22	41.11
Issuance of Preferred Stock	14.51	10.51	-	-	-	-
Net Preferred Stock Issued (Repurchased)	14.51	10.51	-	-	-	-
Preferred Share Dividends Paid	-0.14	-0.23	-	-	-	-
Financing Cash Flow	19.74	15.78	2.98	6.27	-0.22	42.32
Net Cash Flow	6.56	2.86	2.97	-4.59	-3.3	3.67
Free Cash Flow	-13.18	-12.91	-12.9	-8.85	-15.22	-15.61
Free Cash Flow Per Share	-1.05	-2.34	-6.80	-6.57	-14.32	-16.63
Levered Free Cash Flow	-57.71	-35.37	-12.39	-5.77	-22.87	-48.87
Unlevered Free Cash Flow	-12.63	-13.34	-13.59	-11.75	-23.25	-49.58

SEC Filings: 10-K · 10-Q